CN118871432A - 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物 - Google Patents

作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物 Download PDF

Info

Publication number
CN118871432A
CN118871432A CN202380026714.7A CN202380026714A CN118871432A CN 118871432 A CN118871432 A CN 118871432A CN 202380026714 A CN202380026714 A CN 202380026714A CN 118871432 A CN118871432 A CN 118871432A
Authority
CN
China
Prior art keywords
methyl
butyl
pentyl
hexyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026714.7A
Other languages
English (en)
Chinese (zh)
Inventor
徐三甲
李菁
王志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beone Pharmaceutical Suzhou Co Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN118871432A publication Critical patent/CN118871432A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380026714.7A 2022-03-15 2023-03-14 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物 Pending CN118871432A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/080837 2022-03-15
CN2022080837 2022-03-15
PCT/CN2023/081281 WO2023174250A1 (en) 2022-03-15 2023-03-14 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5

Publications (1)

Publication Number Publication Date
CN118871432A true CN118871432A (zh) 2024-10-29

Family

ID=88022264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026714.7A Pending CN118871432A (zh) 2022-03-15 2023-03-14 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物

Country Status (5)

Country Link
US (1) US20250000854A1 (https=)
EP (1) EP4493555A4 (https=)
JP (1) JP2025509404A (https=)
CN (1) CN118871432A (https=)
WO (1) WO2023174250A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121159457A (zh) * 2025-11-20 2025-12-19 英矽智能科技(上海)有限公司 Prmt5抑制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024008176A1 (zh) * 2022-07-07 2024-01-11 西藏海思科制药有限公司 一种可抑制prmt5·mta的杂环化合物及其用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
TW202521525A (zh) 2023-08-09 2025-06-01 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基化合物、其製備方法及其在醫藥上的應用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331765A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
HUE030613T2 (en) * 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
GB201604027D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
IL290341B2 (en) * 2019-09-12 2024-11-01 Mirati Therapeutics Inc Mta-cooperative prmt5 inhibitors
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121159457A (zh) * 2025-11-20 2025-12-19 英矽智能科技(上海)有限公司 Prmt5抑制剂
CN121159457B (zh) * 2025-11-20 2026-03-17 英矽智能科技(上海)有限公司 Prmt5抑制剂

Also Published As

Publication number Publication date
EP4493555A1 (en) 2025-01-22
US20250000854A1 (en) 2025-01-02
WO2023174250A1 (en) 2023-09-21
EP4493555A4 (en) 2026-03-25
JP2025509404A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN118871432A (zh) 作为prmt5的mta协同抑制剂的4-(氨基甲基)-6-(1-甲基-1h-吡唑-4-基)异喹啉-1(2h)-酮衍生物
ES2903423T3 (es) Inhibidores de la desmetilasa 1 específica de lisina
JP5546693B2 (ja) ピラゾロキノリン誘導体
CN111315747B (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
JP6047556B2 (ja) Ｌｒｒｋ２キナーゼ活性の阻害剤
TW201400486A (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒□衍生物
CN109867675A (zh) 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
KR20230129627A (ko) 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물
JP7806015B2 (ja) ピリダジン誘導体遊離塩基の結晶形態、並びにその調製方法及びその使用
EA016108B1 (ru) [2,6]нафтиридины, применимые в качестве ингибиторов протеинкиназы
WO2021099832A2 (en) Adenosine receptor antagonist compounds
CN119095840A (zh) 作为周期蛋白依赖性激酶抑制剂的经取代的6-(嘧啶-4-基)喹啉化合物
CN119707931A (zh) 作为prmt5的mta协同抑制剂的1-(1-氧代-1,2-二氢酞嗪-6-基)环烷基-1-甲酰胺衍生物的中间体和合成方法
CN107501270B (zh) 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
CN109384785B (zh) 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
CN115745955A (zh) 嘧啶酮类化合物、其制备方法及其在医药上的应用
CN118255713B (zh) 一种萘酰胺类化合物、其制备方法及其应用
CN114621256B (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN119100968A (zh) 一种抑制tead活性的并环化合物、其制备方法及应用
CN120548313A (zh) 作为PRMT5的MTA协同抑制剂的5-氨基-1H-吡咯并[3,2-b]吡啶-2-甲酰胺衍生物
EP3889156A1 (en) Nitrogen-containing heterocyclic compound and composition thereof, preparation method therefor, and application thereof
CN117946077A (zh) 作为周期蛋白依赖性激酶抑制剂的经取代的6-(嘧啶-4-基)喹啉化合物
WO2025040140A1 (en) Substituted pyrazol-4-yl urea as kinase inhibitors
CN118255714A (zh) 受体酪氨酸激酶抑制剂、其制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20251024

Address after: 215002 Jiangsu Province Suzhou City China (Shanghai) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Jinhai Road 29.NO

Applicant after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd.

Country or region after: China

Address before: 94 sonaris Avenue, kamana Bay, grand caiman, British Isles

Applicant before: BEIGENE, Ltd.

Country or region before: Cayman Islands

TA01 Transfer of patent application right